Sign In
Buy IFRX
$1.70
-0.0200 (-1.16%)
At Close: Jul 31, 2026
InflaRx's Vilobelimab Hits Primary Endpoint Goal In Late-Stage ANCA-Associated Vasculitis Study
07:15am, Wednesday, 12'th May 2021
InflaRx NV (NASDAQ: IFRX) has announced topline results from its U.S. Phase 2 IXPLORE study evaluating vilobelimab in patients with anti-neutrophil cytoplasmic auto-antibody (ANCA)-associated va
InflaRx Announces Positive Topline Results for Vilobelimab from the U.S. Phase II ANCA-Associated Vasculitis IXPLORE Study
04:30pm, Tuesday, 11'th May 2021
JENA, Germany, May 11, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announc
InflaRx Reports Full Year 2020 Financial & Operating Results
06:30am, Thursday, 25'th Mar 2021
JENA, Germany, March 25, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, annou
InflaRx to Present at Upcoming Investor Conferences
07:30am, Wednesday, 03'rd Mar 2021
InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced that management will present at tw
InflaRx Announces Closing of $75 Million Public Offering of Common Shares and One-Year Warrants
04:01pm, Monday, 01'st Mar 2021
JENA, Germany, March 01, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,
InflaRx Announces Proposed Offering of Common Shares and One-Year Warrants
04:01pm, Wednesday, 24'th Feb 2021
JENA, Germany, Feb. 24, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, a
InflaRx's Vilobelimab Suppresses Inflammation In Mid-Stage Chronic Skin Disorder Study
09:11am, Thursday, 11'th Feb 2021
InflaRx NV (NASDAQ: IFRX) has announced new data Phase 2b SHINE study, evaluating vilobelimab (IFX-1) in moderate and severe Hurley Stage II and III hidradenitis suppurativa (HS), a chronic skin c
JENA, Germany, Feb. 11, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today
InflaRx Provides Update on Vilobelimab (IFX-1) Development
07:30am, Monday, 11'th Jan 2021
JENA, Germany, Jan. 11, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today
InflaRx to Present at Upcoming Annual J.P. Morgan Healthcare Conference
07:30am, Thursday, 07'th Jan 2021
JENA, Germany, Jan. 07, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, w
InflaRx Completes Enrollment in Vilobelimab (IFX-1) European Phase II Study in ANCA-associated Vasculitis
07:30am, Tuesday, 05'th Jan 2021
JENA, Germany, Jan. 05, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announ
7 Biotech Penny Stocks Worth a Gamble
11:50am, Wednesday, 11'th Nov 2020
With the pandemic drawing much attention toward biotech stocks, there are some interesting ideas among in the small-cap field, but only if you understand the severe risks involved. The post 7 Biotech
InflaRx Reports Q3 2020 Financial & Operating Results
07:00am, Thursday, 29'th Oct 2020
JENA, Germany, Oct. 29, 2020 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announ
InflaRx to Present at Upcoming Virtual Investor Events
11:30am, Thursday, 06'th Aug 2020
JENA, Germany, Aug. 06, 2020 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, w
InflaRx Reports Q2 2020 Financial & Operating Results
11:30am, Thursday, 30'th Jul 2020
* Announced encouraging results from the Phase II portion of the Phase II/III adaptive, randomized, controlled trial in patients with COVID-19 induced pneumonia, showing a trend in lower 28-day all-ca
